- Home
- WING vs NUVL Comparison
WING vs NUVL Comparison
Compare WING & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WING
- NUVL
- Stock Information
- Founded
- WING 1994
- NUVL 2017
- Country
- WING United States
- NUVL United States
- Employees
- WING N/A
- NUVL N/A
- Industry
- WING Restaurants
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- WING Consumer Discretionary
- NUVL Health Care
- Exchange
- WING Nasdaq
- NUVL Nasdaq
- Market Cap
- WING 6.7B
- NUVL 7.1B
- IPO Year
- WING 2015
- NUVL 2021
- Fundamental
- Price
- WING $229.24
- NUVL $106.81
- Analyst Decision
- WING Strong Buy
- NUVL Strong Buy
- Analyst Count
- WING 25
- NUVL 13
- Target Price
- WING $343.33
- NUVL $133.85
- AVG Volume (30 Days)
- WING 1.1M
- NUVL 620.3K
- Earning Date
- WING 11-04-2025
- NUVL 10-30-2025
- Dividend Yield
- WING 0.52%
- NUVL N/A
- EPS Growth
- WING 79.44
- NUVL N/A
- EPS
- WING 6.14
- NUVL N/A
- Revenue
- WING $682,980,000.00
- NUVL N/A
- Revenue This Year
- WING $18.13
- NUVL N/A
- Revenue Next Year
- WING $19.10
- NUVL N/A
- P/E Ratio
- WING $37.66
- NUVL N/A
- Revenue Growth
- WING 15.55
- NUVL N/A
- 52 Week Low
- WING $204.00
- NUVL $55.54
- 52 Week High
- WING $388.14
- NUVL $112.53
- Technical
- Relative Strength Index (RSI)
- WING 42.36
- NUVL 62.23
- Support Level
- WING $229.67
- NUVL $93.05
- Resistance Level
- WING $251.06
- NUVL $112.53
- Average True Range (ATR)
- WING 14.01
- NUVL 5.86
- MACD
- WING 0.20
- NUVL 0.57
- Stochastic Oscillator
- WING 45.36
- NUVL 65.59
About WING Wingstop Inc.
Founded in 1994 in Garland, Texas, Wingstop is a restaurant operator specializing in indulgent bone-in and boneless chicken wings, chicken tenders, fries, and, recently, chicken sandwiches. The firm's footprint has grown quickly since its inception, expanding to 2,818 global stores at the end of the second quarter of 2025. With a 98% franchised model, Wingstop generates the lion's share of its revenue from franchise royalties and advertising fees, with the remainder derived from a small footprint of company-owned stores.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.